Nuo Therapeutics

Nuo Therapeutics

Nuo Therapeutics' corporate lineage traces back to Cytomedix, a company that secured FDA clearance for the Angel concentrated platelet-rich plasma system before a 2016 reverse merger with the original Nuo Therapeutics created a combined entity focused on cellular therapies. The firm's signature technology, the Aurix system, produces an autologous platelet-rich plasma gel from a patient's own blood and won FDA clearance for non-healing chronic wounds. David E. Jorden, who previously served as CFO, assumed the CEO role during a period of financial restructuring that included multiple capital raises and a Chapter 11 bankruptcy reorganization filing in early 2023. The company's strategy centers on biologics for advanced wound care, pursued through the Aurix Gel platform targeting diabetic foot ulcers and venous leg ulcers — indications with established Medicare reimbursement codes that provide a potential path to commercialization. Nuo previously maintained a regenerative therapies division exploring orthopedic and soft-tissue applications, but available public disclosures suggest a narrow operational focus on the wound-care indication amid constrained balance-sheet capacity. The firm has not announced material partnerships with large pharmaceutical distributors or contract research organizations. Following a series of delisting threats from the NYSE American exchange, the firm filed a voluntary Chapter 11 petition in January 2023 in the District of Delaware, citing the need to restructure secured convertible debentures and trade liabilities — a process that converted the company into a privately held entity by mid-2023. Post-restructuring ownership remains unclear, though pre-petition public disclosures showed a fragmented retail shareholder base alongside a handful of healthcare-focused institutional investors. No filings detail a dedicated in-house sales force or national account team for market access. Nuo Therapeutics' structural differentiator is its status as a post-bankruptcy, formerly public micro-cap biotech operating outside the traditional family office or venture-backed startup architecture. Its platform asset, Aurix, has FDA clearance but minimal market penetration. Future viability hinges on execution under a restructured balance sheet with no disclosed backing from strategic pharmaceutical partners or diversified family-office allocators — a rare posture that makes the company's access to growth capital the single most determining factor in whether the technology reaches patients at scale.